Beta

Tevogen bio holdings inc.TVGN.US Overview

US StockHealthcare
(No presentation for TVGN)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

TVGN AI Insights

TVGN Overall Performance

TVGN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TVGN Recent Performance

-7.29%

Tevogen bio holdings inc.

-1.10%

Avg of Sector

-0.49%

S&P500

TVGN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check TVGN's Trend

TVGN Key Information

TVGN Valuation Metrics

TVGN Profile

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Price of TVGN

TVGN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TVGN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.44
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is TVGN's latest earnings report released?

    The most recent financial report for Tevogen bio holdings inc. (TVGN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TVGN's short-term business performance and financial health. For the latest updates on TVGN's earnings releases, visit this page regularly.

  • How much debt does TVGN have?

    As of the end of the reporting period, Tevogen bio holdings inc. (TVGN) had total debt of 7.5M, with a debt ratio of 1.71. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TVGN have?

    At the end of the period, Tevogen bio holdings inc. (TVGN) held Total Cash and Cash Equivalents of 552.37K, accounting for 0.13 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TVGN's EPS continuing to grow?

    According to the past four quarterly reports, Tevogen bio holdings inc. (TVGN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -2.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TVGN?

    Tevogen bio holdings inc. (TVGN)'s Free Cash Flow (FCF) for the period is -2.25M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 26.31% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TVGN?

    The latest valuation data shows Tevogen bio holdings inc. (TVGN) has a Price-To-Earnings (PE) ratio of -0.7 and a Price/Earnings-To-Growth (PEG) ratio of 0.15. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.